Mass General Brigham Cancer Institute's Bone Marrow Transplant (BMT) Program is world-renowned for its expertise in hematopoietic cell transplantation (HCT) to treat a wide variety of hematological conditions. Since the BMT program’s inception in 1992, we have conducted over 3,000 transplant procedures and currently conduct over 150 transplant procedures annually. In addition to comprehensive and compassionate multi-disciplinary care for our patients, we also conduct leading-edge clinical, translational, and supportive care research to develop innovative strategies for improving the outcomes and lives of patients undergoing BMT.